INNOVATIVE THERAPIES FOR TREATING ALL DMD PATIENTS
Duchenne Muscular Dystrophy (DMD) is a devastating genetic disease. Currently, there is no cure for DMD. We at MyoArete are committed toward developing innovative therapies for treating all DMD patients.
The MyoArete pipeline consists of utrophin upregulation-based products for treatments for DMD. These treatments are predicted to benefit all DMD patients, regardless of mutation.
MyoArete is an innovative biopharmaceutical startup focused on developing cures for DMD. We use new platform technologies developed at the founder's laboratory at the University of Pennsylvania and exclusively licensed to MyoArete.
Tejvir S. Khurana, MD, PhD. ,
Department of Physiology & Pennsylvania Muscle Institute,
Perelman School of Medicine, University of Pennsylvania,
750 Clinical Research Building (CRB),
415 Curie Boulevard,
Philadelphia, PA 19104-6085
Neal Lemon, PhD, MBA,
Penn Center for Innovation (PCI) Licensing Group,
University of Pennsylvania
3600 Civic Center Boulevard, 9th Floor
Philadelphia, PA 19104